In this scenario, PKC acts as a driving factor, and PLD is a crucial regulator of PKC-dependent mTOR activation; as a result, cancer cells become more susceptible to PLD and mTOR inhibitors [84]. This evidence concerns the gene PRRT2 and cancer.